Literature DB >> 16724666

Thalidomide radiosensitization of normal murine hematopoietic but not squamous cell carcinoma or multiple myeloma tumor cell lines.

Michael W Epperly1, Emily E Greenberger, Darcy Franicola, Samuel Jacobs, Joel S Greenberger.   

Abstract

BACKGROUND: Thalidomide (TL), due to its antiangiogenic effects, has been postulated to be a potential radiosensitizer of multiple myeloma and squamous tumors in vivo.
MATERIALS AND METHODS: To determine whether TL was a radiosensitizer, 32D cl 3 cells (hematopoietic progenitor) as well as SCC-VII (squamous cell carcinoma), OPM1 or OPM2 (multiple myeloma) tumor cells were irradiated to doses ranging from 0 to 8 Gy and then plated in 0, 50 or 150 microM TL in each of three protocols: i) 1 hour before irradiation; ii) 1 hour before irradiation and also in medium following irradiation; or iii) placed in TL containing medium following irradiation.
RESULTS: Using 150 microM TL (which did not stimulate cell growth) the 32D cl 3 cells had increased radiation sensitivity compared to the control irradiated cells. In contrast, the SCC-VII, OPMI or OPM2 cells showed no detectable radiosensitization when incubated in TL before, during or after irradiation compared to the control irradiated cells.
CONCLUSION: These results demonstrated that TL may be a selective radiosensitizer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16724666

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  3 in total

1.  Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study.

Authors:  Nadia Wiazzane; Cyrus Chargari; Corine Plancher; Jerome Tamburini; Bernard Asselain; Alain Fourquet; Didier Bouscary; Youlia M Kirova
Journal:  World J Radiol       Date:  2013-06-28

2.  Small animal absorbed radiation dose from serial micro-computed tomography imaging.

Authors:  Stephanie K Carlson; Kelly L Classic; Claire E Bender; Stephen J Russell
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

Review 3.  Radiotherapy and "new" drugs-new side effects?

Authors:  Maximilian Niyazi; Cornelius Maihoefer; Mechthild Krause; Claus Rödel; Wilfried Budach; Claus Belka
Journal:  Radiat Oncol       Date:  2011-12-21       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.